Pipeline

June 24, 2019

Company	Drug/Device	Medical Condition	Status
Cellular Biomedicine Group Inc.	anti-CD20 CAR-T	diffuse large B-cell lymphoma (DLBCL)	Phase I trial initiated enrolling 12 subjects in China
Boehringer Ingelheim OSE Immunotherapeutics SA	SIRPα antagonist monoclonal antibody BI 765063 (formerly OSE-172)	advanced solid tumors	Phase I trial initiated
Rocket Pharmaceuticals, Inc.	RP-A501	Danon disease	Phase I trial initiated enrolling 12-24 pediatric and young adult male subjects
BioNTech SE Genmab A/S	DuoBody-PD-L1x4-1BB	metastatic or unresectable malignant solid tumors	Phase I/IIa trial initiated
Reistone Biopharma Company	SHR0302	Ulcerative Colitis	Phase II trial initiated
Reistone Biopharma Company	SHR0302	Crohn's disease	Phase II trial initiated
Zydus Cadila	Saroglitazar Magnesium	Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH)	Phase II trial initiated enrolling 104 subjects at 20 sites across the U.S.
InflaRx N.V.	IFX-1	Pyoderma Gangraenosum (PG)	Phase IIa trial initiated enrolling 12 subjects with moderate to severe PG at three sites in Canada
Corvidia Therapeutics Inc.	Ziltivekimab (previously known as COR-001)	advanced chronic kidney disease (CKD)	Phase IIb trial initiated enrolling 240 subjects at 50 sites across the U.S.
Arena Pharmaceuticals, Inc.	etrasimod 2 mg	ulcerative colitis (UC)	Phase III trial initiated enrolling subjects with moderately to severely active UC
OxThera AB	Oxabact	Primary Hyperoxaluria	Phase III trial initiated enrolling 22 subjects at 10 sites across Europe and the U.S.
Torque	TRQ-1501	relapsed or refractory solid tumors and lymphomas that express any of five tumor-associated antigens (PRAME, WT-1, SSX2, Survivin and NY-ESO-1)	Fast Track designation granted by the FDA
Bio-Techne	ExoDx Prostate IntelliScore (EPI) test	prostate cancer	Breakthrough Device designation granted by the FDA
Camurus	CAM2029	acromegaly	IND approval granted by the FDA
Triumvira Immunologics, Inc.	TAC01-CD19	CD19-postive B-cell malignancies	IND approval granted by the FDA
Amgen Allergan plc	KAJINTI (trastuzumab-anns)	HER2-overexpressing adjuvant and metastatic breast cancer	Approval granted by the FDA
Amgen Allergan plc	KAJINTI (trastuzumab-anns)	HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma	Approval granted by the FDA
Novo Nordisk	Victoza (liraglutide)	Type 2 diabetes in children and adolescents aged 10-17 years	Approval granted by the FDA
Kowa Pharmaceuticals America, Inc.	LIVALO (pitavastatin)	heterozygous familial hypercholesterolemia (HeFH) in subjects eight years and older	Approval granted by the FDA